Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.
Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.
TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
TCG Crossover's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Pharmaceutical. The firm invests across 10 different industry categories.
Among tracked funding rounds, Upstream Bio received $200.0M in a Series B round. TCG Crossover's total known invested capital is $14.3B.
TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.
Recent TCG Crossover portfolio additions include Entrada Therapeutics, Tourmaline Bio, Alpine Immune Sciences, Upstream Bio, Alkeus Pharmaceuticals. These companies were founded in 2020 or later.